Understand the source comparison
SS-LUP-332 Muscle Performance Complete Guide 2026: Comparison Table
Before presenting product comparisons, it's essential to understand how SS-LUP-332 differs mechanistically from other endurance-enhancing compounds under investigation. SS-LUP-332 Rev-Erbα agonist → mitochondrial biogenesis, fatty acid oxidation 70% endurance
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before presenting product comparisons, it's essential to understand how SS-LUP-332 differs mechanistically from other endurance-enhancing compounds under investigation.
- SS-LUP-332
- Rev-Erbα agonist → mitochondrial biogenesis, fatty acid oxidation
- 70% endurance increase (sedentary mice, 28 days)
- None
- Research-grade only
- Strongest genetic-level evidence for oxidative remodeling—no human safety or efficacy data
- GW501516 (Cardarine)
- PPARδ agonist → fatty acid oxidation, mitochondrial function
- 68% endurance increase (mice, 8 weeks)
- Withdrawn Phase II trials
- Banned by WADA
- Discontinued due to cancer risk in rodents—not pursued further
- AICAR
- AMPK activator → glucose uptake, mitochondrial biogenesis
- 44% endurance increase (mice, 4 weeks)
- Limited Phase I data
- Research compound
- Lower potency than Rev-Erbα agonists—requires high doses
- MK-677
- Growth hormone secretagogue
- Indirect via IGF-1 → muscle protein synthesis
- Phase II completed
- Not FDA-approved
- Increases lean mass, not oxidative capacity—different pathway entirely